Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
May 13, 2013


Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
May 13, 2013


Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
May 6, 2013


Spine Wave Announces U.S. FDA’s 510K Clearance of the StaXx® IB System, an Intervertebral Body Fusion Device
April 29, 2013


Durata Therapeutics Closes Public Offering of Common Stock
April 17, 2013


Chimerix Announces Pricing of Initial Public Offering
April 11, 2013


Oxford Immunotec wins 2013 Red Herring Top 100 Award
April 11, 2013


MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model
April 10, 2013


iRhythm Secures $16 Million in Funding Led by Norwest Venture Partners to Fuel Continued Market and Technology Expansion
April 10, 2013


NxStage Completes Move to Direct Sales In UK
April 8, 2013


MEI Pharma Announces $15.2 Million Registered Offering of Common Stock
April 5, 2013


VaxInnate Awarded U.S. Government Grant to Develop Dengue Vaccine
April 4, 2013


Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
March 21, 2013


NeuroStar TMS Therapy, a Non-Drug Depression Treatment, Demonstrates Statistically Significant Benefits on Patient-Reported Pain Outcomes
March 19, 2013


Douglas Harrington, MD Addresses Select Group of Physicans Regarding Latest Advances in Cardiovascular Risk Assessment
March 19, 2013


Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology
March 14, 2013


Direct Flow Medical® Transcatheter Aortic Valve System Demonstrates Excellent Six-Month Outcomes In Discover Trial
March 12, 2013


Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
March 5, 2013


AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device
February 27, 2013


ReShape Medical Completes Enrollment of Pivotal Clinical Trial for Weight Loss Device
February 25, 2013


Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
February 25, 2013


NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
February 25, 2013


Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
February 20, 2013


Oxford Immunotec and Lophius Biosciences sign licensing and collaboration agreements
January 29, 2013


Pearl Therapeutics Strengthens Its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development
January 17, 2013


athenahealth to Acquire Mobile Health Leader Epocrates
January 7, 2013


Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia
January 2, 2013